Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Jasper Therapeutics (JSPR – Research Report). The associated price target remains the same with $40.00.
Emily Bodnar’s rating is based on the promising developments in Jasper Therapeutics’ approach to chronic urticaria treatment. The recent presentation of BEACON data at the American Academy of Dermatology highlighted significant advancements in understanding and managing this condition. The data underscored the importance of targeting specific pathways and cells, such as mast cells and basophils, which play a crucial role in the pathogenesis of chronic spontaneous urticaria (CSU).
Furthermore, the introduction of anti-KIT antibodies, which can deplete mast cells rather than merely inactivate them, represents a groundbreaking advancement in treatment options. These developments, coupled with the potential of new agents like barzolvolimab and briquilimab, suggest a robust pipeline that could address unmet needs in CSU treatment. Such innovations and the strategic focus on novel therapeutic pathways contribute to Bodnar’s optimistic outlook and Buy rating for Jasper Therapeutics.
In another report released on March 3, JMP Securities also maintained a Buy rating on the stock with a $70.00 price target.